Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 61 articles: HTML format

Single Articles

March 2026
1. ARMSTRONG AJ, Azad AA, Iguchi T, Stenzl A, et al
   Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.
   J Clin Oncol. 2026 Mar 27:JCO2402829. doi: 10.1200/JCO-24-02829.
   PubMed     Abstract available
   
   
   
2. VALLE LF, Calais J, Kishan AU
   Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer.
   J Clin Oncol. 2026 Mar 18:JCO2600241. doi: 10.1200/JCO-26-00241.
   PubMed    
   
   
   
3. BOLEK H, Urun Y
   Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate Cancer.
   J Clin Oncol. 2026 Mar 18:JCO2502722. doi: 10.1200/JCO-25-02722.
   PubMed    
   
   
   February 2026
4. ARMSTRONG AJ, Morris MJ, Abida W, Aggarwal RR, et al
   Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.
   J Clin Oncol. 2026 Feb 26:JCO2502834. doi: 10.1200/JCO-25-02834.
   PubMed     Abstract available
   
   
   January 2026
5. STISH BJ, Mazza GL, Nauseef JT, Humeniuk MS, et al
   Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
   J Clin Oncol. 2026 Jan 26:JCO2501486. doi: 10.1200/JCO-25-01486.
   PubMed     Abstract available
   
   
   
6. TAPLIN ME, Riaz IB, Rumble RB, Naqvi SAA, et al
   Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1.
   J Clin Oncol. 2026 Jan 20:JCO2502693. doi: 10.1200/JCO-25-02693.
   PubMed     Abstract available
   
   
   
7. ZHANG Y, Wang X, Hu H
   Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.
   J Clin Oncol. 2026 Jan 12:JCO2502107. doi: 10.1200/JCO-25-02107.
   PubMed    
   
   
   
8. POS FJ, Menne Guricova K, van der Voort van der Zyp JRN, Smeenk RJ, et al
   Reply to: Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.
   J Clin Oncol. 2026 Jan 12:JCO2502744. doi: 10.1200/JCO-25-02744.
   PubMed    
   
   
   November 2025
9. KISHAN AU, Valle LF, Wilhalme H, Felix C, et al
   (177)Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study.
   J Clin Oncol. 2025 Nov 12:JCO2501553. doi: 10.1200/JCO-25-01553.
   PubMed     Abstract available
   
   
   October 2025
10. FLESHNER NE, Bernardino RM, Izawa J, Drachenberg D, et al
    Metformin Active Surveillance Trial in Low-Risk Prostate Cancer.
    J Clin Oncol. 2025 Oct 30:JCO2501070. doi: 10.1200/JCO-25-01070.
    PubMed     Abstract available
    
    
    
11. EINSTEIN DJ, Abel ML, Aragon-Ching JB, Arlen PM, et al
    National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
    J Clin Oncol. 2025 Oct 23:JCO2501693. doi: 10.1200/JCO-25-01693.
    PubMed     Abstract available
    
    
    
12. LIN JK, Niu J, Giordano SH, Li P, et al
    Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers.
    J Clin Oncol. 2025;43:3254-3265.
    PubMed     Abstract available
    
    
    
13. LI J, Huang R, Hu H
    Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.
    J Clin Oncol. 2025 Oct 3:JCO2501476. doi: 10.1200/JCO-25-01476.
    PubMed    
    
    
    
14. TRAN PT, Wang JH, Tang C, Kiess AP, et al
    Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.
    J Clin Oncol. 2025 Oct 3:JCO2501855. doi: 10.1200/JCO-25-01855.
    PubMed    
    
    
    August 2025
15. MENNE GURICOVA K, Draulans C, Pos FJ, Kerkmeijer LGW, et al
    Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: 10-Year Outcomes of the FLAME Trial.
    J Clin Oncol. 2025 Aug 4:JCO2500274. doi: 10.1200/JCO-25-00274.
    PubMed     Abstract available
    
    
    July 2025
16. SAYEGH N, Ozay ZI, Zhang T, Agarwal N, et al
    Precision and Combination Strategies for Immune Checkpoint Inhibitors in Prostate Cancer.
    J Clin Oncol. 2025 Jul 28:JCO2501009. doi: 10.1200/JCO-25-01009.
    PubMed    
    
    
    
17. LEONE G, Wong YNS, Jones RJ, Sankey P, et al
    Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study.
    J Clin Oncol. 2025 Jul 28:JCO2402637. doi: 10.1200/JCO-24-02637.
    PubMed     Abstract available
    
    
    June 2025
18. WANG JH, Sherry AD, Bazyar S, Sutera P, et al
    Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
    J Clin Oncol. 2025;43:2059-2068.
    PubMed     Abstract available
    
    
    
19. STEIN MN, Vinceneux A, Robbrecht D, Doger B, et al
    Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase 1 Study.
    J Clin Oncol. 2025 Jun 1:101200JCO2500678. doi: 10.1200/JCO-25-00678.
    PubMed     Abstract available
    
    
    May 2025
20. HASSANZADEH C, Kuban D, Pasyar S, Bassett R, et al
    Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial.
    J Clin Oncol. 2025 May 14:JCO2402057. doi: 10.1200/JCO-24-02057.
    PubMed     Abstract available
    
    
    
21. GARJE R, Riaz IB, Naqvi SAA, Rumble RB, et al
    Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
    J Clin Oncol. 2025 May 2:JCO2500007. doi: 10.1200/JCO-25-00007.
    PubMed     Abstract available
    
    
    April 2025
22. KUNZ N, Kemper C
    Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as Prostate Cancer Treatment.
    J Clin Oncol. 2025 Apr 22:JCO2500457. doi: 10.1200/JCO-25-00457.
    PubMed    
    
    
    
23. ARMSTRONG AJ, Liu VYT, Selvaraju RR, Chen E, et al
    Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials.
    J Clin Oncol. 2025 Apr 16:JCO2400365. doi: 10.1200/JCO.24.00365.
    PubMed     Abstract available
    
    
    March 2025
24. AGGARWAL RR, Vuky J, VanderWeele D, Rettig M, et al
    Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2025 Mar 26:JCO2401989. doi: 10.1200/JCO-24-01989.
    PubMed     Abstract available
    
    
    
25. SLOVIN SF
    Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why?
    J Clin Oncol. 2025 Mar 13:JCO2402402. doi: 10.1200/JCO-24-02402.
    PubMed    
    
    
    
26. PETRYLAK DP, Ratta R, Matsubara N, Korbenfeld E, et al
    Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
    J Clin Oncol. 2025 Mar 5:JCO2401283. doi: 10.1200/JCO-24-01283.
    PubMed     Abstract available
    
    
    January 2025
27. SAAD F, Vjaters E, Testa I, Haresh KP, et al
    Reply to: Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
    J Clin Oncol. 2025 Jan 17:JCO2402742. doi: 10.1200/JCO-24-02742.
    PubMed    
    
    
    
28. MITTAL A, Linford G, Gyawali B
    Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.
    J Clin Oncol. 2025 Jan 17:JCO2402314. doi: 10.1200/JCO-24-02314.
    PubMed    
    
    
    
29. YU EY, Rumble RB, Agarwal N, Cheng HH, et al
    Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline.
    J Clin Oncol. 2025 Jan 9:JCO2402608. doi: 10.1200/JCO-24-02608.
    PubMed     Abstract available
    
    
    December 2024
30. DIZMAN N, Necchi A
    Promises and Challenges of Dietary Intervention in Patients With Prostate Cancer: Lessons Learned From the CAPFISH-3 Trial.
    J Clin Oncol. 2024 Dec 13:JCO2402444. doi: 10.1200/JCO-24-02444.
    PubMed    
    
    
    
31. ARONSON WJ, Grogan T, Liang P, Jardack P, et al
    High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial.
    J Clin Oncol. 2024 Dec 13:JCO2400608. doi: 10.1200/JCO.24.00608.
    PubMed     Abstract available
    
    
    October 2024
32. BROOKS JD
    Stockholm3 in a Multiethnic Cohort: Optimizing Prostate Cancer Screening to Reduce Harm and Improve Equity.
    J Clin Oncol. 2024 Oct 3:JCO2400941. doi: 10.1200/JCO.24.00941.
    PubMed    
    
    
    September 2024
33. MONTORSI F, Longoni M, Briganti A, Gandaglia G, et al
    Improving Assessment of Radiorecurrent Prostate Cancer: Implications for Salvage Reirradiation.
    J Clin Oncol. 2024 Sep 17:JCO2401067. doi: 10.1200/JCO.24.01067.
    PubMed    
    
    
    
34. SAAD F, Vjaters E, Shore N, Olmos D, et al
    Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.
    J Clin Oncol. 2024 Sep 16:JCO2401798. doi: 10.1200/JCO-24-01798.
    PubMed     Abstract available
    
    
    
35. TOMBAL B, Giannarini G
    Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How.
    J Clin Oncol. 2024 Sep 6:JCO2401134. doi: 10.1200/JCO.24.01134.
    PubMed    
    
    
    July 2024
36. VIGNESWARAN HT, Eklund M, Discacciati A, Nordstrom T, et al
    Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA): A Prospective Multicentered Trial.
    J Clin Oncol. 2024 Jul 22:JCO2400152. doi: 10.1200/JCO.24.00152.
    PubMed     Abstract available
    
    
    June 2024
37. GARCIA JA, Spratt DE
    Is It Premature to Accept Radiographic Progression-Free Survival as a Surrogate End Point in Metastatic Hormone-Sensitive Prostate Cancer?
    J Clin Oncol. 2024 Jun 14:JCO2400210. doi: 10.1200/JCO.24.00210.
    PubMed    
    
    
    May 2024
38. LEE WR, Dignam JJ, Amin MB, Bruner DW, et al
    Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
    J Clin Oncol. 2024 May 17:JCO2302445. doi: 10.1200/JCO.23.02445.
    PubMed     Abstract available
    
    
    
39. EINSTEIN DJ, Regan MM, Stevens JS, McDermott DF, et al
    Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial.
    J Clin Oncol. 2024 May 16:JCO2400279. doi: 10.1200/JCO.24.00279.
    PubMed     Abstract available
    
    
    
40. SPRATT DE
    Prostate-Specific Antigen Nadir Postradiotherapy in Localized Prostate Cancer: Is It Prognostic or Predictive?
    J Clin Oncol. 2024 May 14:JCO2302689. doi: 10.1200/JCO.23.02689.
    PubMed    
    
    
    
41. SAYAN M, Chen MH, Loffredo M, McMahon E, et al
    Elective Pelvic Lymph Node Radiation Therapy and the Risk of Death in Patients With Unfavorable-Risk Prostate Cancer: A Postrandomization Analysis.
    J Clin Oncol. 2024 May 1:JCO2302394. doi: 10.1200/JCO.23.02394.
    PubMed     Abstract available
    
    
    April 2024
42. EKANGER C, Helle SI, Reisaeter L, Hysing LB, et al
    Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
    J Clin Oncol. 2024 Apr 23:JCO2301391. doi: 10.1200/JCO.23.01391.
    PubMed     Abstract available
    
    
    
43. 
    Erratum: Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2024 Apr 16:JCO2400454. doi: 10.1200/JCO.24.00454.
    PubMed    
    
    
    March 2024
44. YU JB, DeStephano DM, Jeffers B, Horowitz DP, et al
    Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.
    J Clin Oncol. 2024 Mar 20:JCO2301604. doi: 10.1200/JCO.23.01604.
    PubMed     Abstract available
    
    
    
45. MADAN RA, Yu EY, Posadas EM, Lee RJ, et al
    Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care.
    J Clin Oncol. 2024 Mar 15:JCO2302727. doi: 10.1200/JCO.23.02727.
    PubMed     Abstract available
    
    
    
46. FALLAH J, Xu J, Weinstock C, Gao X, et al
    Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
    J Clin Oncol. 2024 Mar 14:JCO2302105. doi: 10.1200/JCO.23.02105.
    PubMed     Abstract available
    
    
    
47. KWAK L, Ravi P, Armstrong JG, Beckendorf V, et al
    Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
    J Clin Oncol. 2024 Mar 12:JCO2300762. doi: 10.1200/JCO.23.00762.
    PubMed     Abstract available
    
    
    
48. HEISS BL, Chang E, Gao X, Truong T, et al
    US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2024 Mar 7:JCO2302182. doi: 10.1200/JCO.23.02182.
    PubMed     Abstract available
    
    
    January 2024
49. AGGARWAL R, Heller G, Hillman DW, Xiao H, et al
    PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    J Clin Oncol. 2024 Jan 23:JCO2301157. doi: 10.1200/JCO.23.01157.
    PubMed     Abstract available
    
    
    
50. CHILDS DS, Orme JJ, Ravi P
    Delaying Prostate-Specific Antigen Progression in Biochemically Recurrent Prostate Cancer: Is It Clinically Meaningful?
    J Clin Oncol. 2024 Jan 23:JCO2302410. doi: 10.1200/JCO.23.02410.
    PubMed    
    
    
    
51. HALABI S, Roy A, Rydzewska L, Guo S, et al
    Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2301535. doi: 10.1200/JCO.23.01535.
    PubMed     Abstract available
    
    
    
52. DENMEADE SR
    Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen-Based Therapies for Prostate Cancer.
    J Clin Oncol. 2024 Jan 5:JCO2302310. doi: 10.1200/JCO.23.02310.
    PubMed    
    
    
    December 2023
53. FALLAH J, Xu J, Weinstock C, Brave MH, et al
    FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2023 Dec 21:JCO2301868. doi: 10.1200/JCO.23.01868.
    PubMed     Abstract available
    
    
    November 2023
54. MATEO J, de Bono JS, Fizazi K, Saad F, et al
    Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300339. doi: 10.1200/JCO.23.00339.
    PubMed     Abstract available
    
    
    
55. ROY S, Romero T, Michalski JM, Feng FY, et al
    Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.
    J Clin Oncol. 2023;41:5005-5014.
    PubMed     Abstract available
    
    
    
56. GARJE R, Rumble RB, Parikh RA
    Systemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2023 Nov 6:JCO2302128. doi: 10.1200/JCO.23.02128.
    PubMed     Abstract available
    
    
    
57. TAGAWA ST, Thomas C, Sartor AO, Sun M, et al
    Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591.
    J Clin Oncol. 2023 Nov 3:JCO2300573. doi: 10.1200/JCO.23.00573.
    PubMed     Abstract available
    
    
    October 2023
58. GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al
    Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
    J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949.
    PubMed     Abstract available
    
    
    
59. MADAN RA, Karzai F, VanderWeele DJ, Cheng HH, et al
    Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.
    J Clin Oncol. 2023 Oct 17:JCO2301502. doi: 10.1200/JCO.23.01502.
    PubMed    
    
    
    September 2023
60. FRANCOLINI G, Gaetano Allegra A, Detti B, Di Cataldo V, et al
    Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO).
    J Clin Oncol. 2023 Sep 21:JCO2300985. doi: 10.1200/JCO.23.00985.
    PubMed     Abstract available
    
    
    
61. STAR J, Bandi P, Siegel RL, Han X, et al
    Cancer Screening in the United States During the Second Year of the COVID-19 Pandemic.
    J Clin Oncol. 2023;41:4352-4359.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum